

Application No.: 09/810,883
Attorney Docket No.: TNX 98-08-01
Customer No.: 26839

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-48 (Canceled)

49. (Currently Amended) ~~The bispecific antibody of claim 47, A bispecific antibody, or a binding fragment thereof, comprising a first determinant that binds to an Immunoreceptor Tyrosine-Based Activation Module (ITAM), wherein said ITAM is selected from the group consisting of BCR, Fc ϵ RI, Fc γ RI, Fc γ RIIA, Fc γ RIIIA, and TCR, and a second determinant that binds to an Immunoreceptor Tyrosine-Based Inhibition Module (ITIM), wherein the ITIM is Fc ϵ RII.~~

50. Cancelled.

51. (Currently Amended) A composition comprising the bispecific antibody of claim [[47]] 49, or a binding fragment thereof, and a physiologically acceptable carrier, excipient, or diluent.

52. (Currently Amended) The bispecific antibody of claim [[47]] 49, wherein at least one determinant is humanized, human, chimeric, or an ScFv.

53. Cancelled.

54. Cancelled.

55. (Currently amended) The method of claim [[53]] 56, wherein the bispecific antibody is administered at a concentration range from 0.1 to 1 μ g/ml.

56. (Currently Amended) A method of ameliorating an allergic disease or condition in a mammal comprising administering the bispecific antibody of claim [[47]] 49, or a binding fragment thereof.

57. (NEW) A method of inhibiting the release of TNF- α from a mast cell or a basophil comprising administering the bispecific antibody of claim 49, or a binding fragment thereof.

58. (NEW) A method of inhibiting the release of histamine from a mast cell or a basophil comprising administering the bispecific antibody of claim 49, or a binding fragment thereof.

Application No.: 09/810,883
Attorney Docket No.: TNX 98-08-01
Customer No.: 26839

59. (NEW) A method of ameliorating an allergic disease or condition in a mammal comprising administering the composition of claim 51.
60. (NEW) A method of inhibiting the release of TNF- α from a mast cell or a basophil comprising administering the composition of claim 51.
61. (NEW) A method of inhibiting the release of histamine from a mast cell or a basophil comprising administering the composition of claim 51.